new technologies competing with glp-1 medications 2025 Impact: How GLP-1s Are Changing the Diabetes Treatment Paradigm What's next for GLP-1 innovation:

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

[1] [2] The liver is involved in the metabolism of the peptide structure, but significant hepatic impairment does not dramatically alter elimination times

Culinary medicine and culinary nutrition education for individuals with the capacity to influence health-related behavior change: a scoping review

At the same time, careful screening and monitoring remain important, especially for individuals with eating disorders or mood disorders

Now, a new study presented at the European Congress on Obesity in Istanbul, Turkey, suggests those reports may have merit

It is important to remember that these factors usually only shift the timeline by a small margin, but they can explain why two people might have different experiences when stopping the medication